1. Field of the Invention
The present invention relates to pulse oximetry. More particularly, embodiments of the present invention relate to processing of signals generated by a pulse oximeter.
2. Description of the Related Art
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
In the field of medicine, doctors often desire to monitor certain physiological characteristics of their patients. Accordingly, a wide variety of devices have been developed for monitoring many such physiological characteristics. Such devices provide doctors and other healthcare personnel with the information they need to provide the best possible healthcare for their patients. As a result, such monitoring devices have become an indispensable part of modern medicine.
One technique for monitoring certain physiological characteristics of a patient is commonly referred to as pulse oximetry, and the devices built based upon pulse oximetry techniques are commonly referred to as pulse oximeters. Pulse oximetry may be used to measure various blood flow characteristics, such as the blood oxygen saturation of hemoglobin in arterial blood, the volume of individual blood pulsations supplying the tissue, and/or the rate of blood pulsations corresponding to each heartbeat of a patient. In fact, the “pulse” in pulse oximetry refers to the time-varying amount of arterial blood in the tissue during each cardiac cycle.
Pulse oximeters typically utilize a non-invasive sensor that transmits light through a patient's tissue and that photoelectrically detects the absorption and/or scattering of the transmitted light in such tissue. One or more of the above physiological characteristics may then be calculated based upon the amount of light absorbed or scattered. More specifically, the light passed through the tissue is typically selected to be of one or more wavelengths that may be absorbed or scattered by the blood in an amount correlative to the amount of the blood constituent present in the blood. The amount of light absorbed and/or scattered may then be used to estimate the amount of blood constituent in the tissue using various algorithms.
Sensors exist that are designed to be applied to a patient's forehead. However, a phenomenon called “venous pulsation” may occur in the forehead or other sites that are not on the patient's extremities and cause incorrect sensor readings. Venous pulsation refers to a pulse generated from the return flow of venous blood to the heart. Because the hemoglobin in venous blood has already delivered oxygen to tissue, and due to prominent harmonics in a venous pressure wave, sensor readings based on venous pulsation may result in artificially low calculations of blood oxygen saturation. In addition, pulse rate calculations based on incorrect sensor readings may be double or triple the patient's actual pulse rate.
While the reliability of traditional pulse oximetry techniques may be adversely impacted by artifacts caused by venous pulsation, traditional techniques may fail to recognize venous pulsation as the source of an error. In some cases, physiological parameters may be calculated in the presence of venous pulsation for hours without any indication that the resulting values are incorrect.
Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.
There is provided a method for detecting venous pulsation, including acquiring a first signal corresponding to absorption at a first near-infrared wavelength, acquiring a second signal corresponding to absorption at a second near-infrared wavelength, deriving an offset metric from the first and second signals, and detecting the presence of venous pulsation based on the offset metric.
There is further provided a device for detecting venous pulsation, including a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.
There is further provided a system for detecting venous pulsation, including a sensor configured to emit light at three or more wavelengths into a patient's tissue and detect absorption of the light, and a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.
There is further provided a method of manufacturing a device for detecting venous pulsation, including providing a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.
Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:
One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
Embodiments of the present invention relate to detecting the presence of venous pulsation, when using a forehead pulse oximetry sensor for example, and correcting the errors associated with venous pulsation in calculating a patient's physiological parameters, such as blood oxygen saturation and pulse rate. Specifically, in accordance with present embodiments, a sensor emits and detects a near-infrared wavelength of light in addition to the red and near-infrared wavelengths commonly used to calculate physiological parameters. This third wavelength of light is used to determine whether venous pulsation is occurring and to correct measurements of the commonly used red and near-infrared wavelengths of light when venous pulsation occurs.
In accordance with an exemplary embodiment of the present invention, arterial blood oxygen saturation, commonly denoted as SaO2, may be estimated as a ratio of oxygenated hemoglobin (HbO2) to deoxygenated hemoglobin (Hb) present in a patient's tissue. Hemoglobin is the component of blood which transports oxygen throughout the body. The ratio of HbO2 to Hb can be determined by shining light at certain wavelengths into a patient's tissue and measuring the absorbance of the light. A first wavelength is typically selected at a point in the electromagnetic spectrum where the absorption of HbO2 differs from the absorption of reduced Hb, and a second wavelength is typically selected at a different point in the spectrum where the absorption of Hb and HbO2 differs from those at the first wavelength. For example, wavelength selections for measuring normal blood oxygenation levels typically include a red light emitted at approximately 660 nm and a near-infrared light emitted at approximately 900 nm, although other red and near-infrared wavelengths may be used. A yellow or orange wavelength may be utilized instead of, or in addition to, the red wavelength.
One common technique for estimating SaO2 is to calculate a characteristic known as the ratio-of-ratios (Ratrat) of the absorption of the red light (RED) to the near-infrared light (IR). While various techniques may be utilized to calculate Ratrat, in one common technique in accordance with an exemplary embodiment of the present invention, a sensor is used to emit red and near-infrared light into a patient's tissue and detect the light that is reflected back. Signals indicative of the detected light are conditioned and processed to generate plethysmographs of the detected light over time. A plethysmographic waveform is generally periodic, with a shape between that of a sawtooth and a sinusoid, having both an AC and a DC component. These AC and DC components may be estimated from maximum (MAX) and minimum (MIN) points in a cycle of the waveform, according to the following equations:
AC=MAX−MIN, (1)
DC=(MAX+MIN)/2. (2)
It should be noted that in other embodiments the maximum and minimum measurements are not necessarily employed to determine the AC and DC components. Indeed, the AC and DC components may be obtained by using essentially any pair of points along both the red and near-infrared light waveforms. The AC and DC components of the RED wavelength and IR wavelength signals may then be used to calculate Ratrat according to the following equation:
Ratrat has been observed to correlate well to SaO2. This observed correlation is used to estimate SaO2 based on the measured value of the ratio-of-ratios. This pulse-based estimate of SaO2 is commonly denoted as SpO2.
The pulse oximetry system 10 may also include a multi-parameter patient monitor 24. The multi-parameter patient monitor 24 may be included in the system 10 to provide a central display for information from the monitor 12 and from other medical monitoring devices or systems (not shown). For example, the multi-parameter patient monitor 24 may display a patient's blood oxygen saturation and pulse rate information from the monitor 12 and blood pressure from a blood pressure monitor (not shown). In addition to the monitor 12, or alternatively, the multi-parameter patient monitor 24 may be configured to calculate values for physiological parameters, as described below. The monitor 12 may be communicatively coupled to the multi-parameter patient monitor 24 via a cable 26 or 28 coupled to a sensor input port or a digital communications port, respectively.
In accordance with an exemplary embodiment of the present invention, the emitter 18 includes a RED LED 38, an IR LED 40, and an IRHb LED 42 for emitting light at the wavelengths required to calculate values for physiological parameters, as described below. Alternative light sources may be used in other embodiments of the present invention. For example, a single wide-spectrum light source may be used, and the detector 20 may be configured to detect light only at certain wavelengths. Alternatively, the detector 20 may detect a wide spectrum of wavelengths of light, and the monitor 12 may process only those wavelengths which are of interest. The emitter 18 may shine light at the different wavelengths into the patient's forehead tissue 30.
The detector 20 may be configured to detect the intensity of light at the RED, IR, and IRHb wavelengths in accordance with an exemplary embodiment of the present invention. Light enters the detector 20 after reflecting off tissue in the patient's forehead 30. The detector 20 may measure the intensity of light at each wavelength of interest and convert that measurement into a digital signal. The light intensity is directly related to the absorbance of light in the tissue 30. That is, when more light at a certain wavelength is absorbed, less light of that wavelength is reflected back and detected by the detector 20. After measuring the light and converting it to a digital signal, the detector 20 may send the signal to the monitor 12.
The encoder 32 may contain information about the wavelengths of light emitted by the emitter 18. This information may allow the monitor 12 to select appropriate calibration coefficients for calculating the patient's physiological parameters. The encoder 32 may, for instance, be a resistor. In addition, the encoder 32 may include information about the sensor 14, such as, for example, that it is a forehead sensor. Any information the encoder 32 contains may be communicated to the monitor 12 for processing along with the information about the detected light from detector 20.
The processor 34 in the monitor 12 may be configured to process incoming signals from and send control signals to the sensor 14. Intermediate hardware (not shown) may be included in the monitor 12 to filter or convert incoming signals and to implement outgoing controls. The memory 36 may contain programming to enable processor 34 to calculate values for physiological parameters, as described below, and to implement the process described below in relation to
Recent trials were run in which wide spectrum light was shone into subjects' forehead tissues and the reflectance/absorbance was detected. It was observed from analysis of these trials that the AC signal contains a generally wavelength-independent offset which does not appear to correlate with light absorption in principal blood or tissue components that are typically intended to be measured. This offset was much higher when the subjects were placed in a position in which venous pulsation was likely to occur than when they were not. The addition of a positive wavelength-independent offset to the AC amplitude causes the Ratrat to converge towards a value near 1.0, regardless of the actual SaO2. For typical pulse-oximetry wavelengths, a Ratrat of 1.0 corresponds to an SaO2 near 80%, while a normal adult breathing room air has an SaO2 near 97%. These wavelength-independent offsets in AC amplitude may cause biases in the SpO2 calculation, which are often seen when venous pulsation is present.
The plots shown in
The calculated RatratHb was found to correlate to the presence of venous pulsation.
At wavelengths where hemoglobin has a low absorption, the AC offset is expected to be primarily due to the effects of venous pulsation. Hemoglobin has a sufficiently low absorption at a wavelength in the range of 1,050-1,350 nm. Due to local water and blood pooling, changes in the water component of the AC spectrum were also observed in some subjects. So that these water changes do not confound the detection of venous pulsation, it may be desirable to further narrow the wavelength range to about 1,050-1,160 nm.
In the graphs illustrated in
As a result of these studies, an offset metric may be derived to predict the presence of venous pulsation in subjects with more accuracy than that seen with previous methods of detecting venous pulsation. This offset metric may be the RatratHb itself or a change in RatratHb from historical values (ΔRatratHb).
As illustrated in
An offset metric 72 may be derived from the current RatratHb 66 and the historical values 68. This offset metric 72 may be the difference between the current RatratHb 66 and the historical values 68, denoted ΔRatratHb, the current RatratHb 66, or a combination thereof. The offset metric 72 may be compared to a threshold 74 to determine if the threshold 74 is exceeded (Block 76). Threshold 74 may be a pre-determined value or may be based on the historical values 68 of the RatratHb. For example, in accordance with an exemplary embodiment of the present invention, threshold 74 may be a fixed value for all patients above which venous pulsation is expected to be present. Alternatively, threshold 74 may be a fixed value based on a patient's physical characteristics, such as, for example, sex, weight, race, and age. In accordance with another embodiment, threshold 74 may be a change from a patient's actual historical values 68. That is, threshold 74 may be a fixed value or percentage above a baseline of a patient's historical values 68.
If the offset metric 72 exceeds the threshold 74, the presence of venous pulsation may be reported (Block 78). Reporting venous pulsation (Block 78) may include any suitable method, such as, for example, displaying an error message, sounding an audible alarm, or ceasing display of physiological parameters. Alternatively, or in addition to reporting the presence of venous pulsation (Block 78), corrections may be made in the calculation of other physiological parameters (Block 80) based on the measured AC offset. For example, the AC offset detected in the IRHb wavelength may be corrected for the RED and IR wavelengths by subtracting it from the AC measurements at those wavelengths before physiological parameters are calculated.
If the offset metric 72 does not exceed the threshold 74, the presence of venous pulsation may not be reported (Block 82). Regardless of the outcome of the comparison (Block 76) of the offset metric 72 to the threshold 74, the process 60 continues by returning to the calculation of RatratHb (Block 64) for new detected measurements of IR and IRHb.
While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Indeed, the but these techniques may not only be applied to measurements of blood oxygen saturation, but these techniques may also be utilized for the measurement and/or analysis of other blood constituents. For example, using the same, different, or additional wavelengths, the present techniques may be utilized in conjunction with the measurement and/or analysis of carboxyhemoglobin, met-hemoglobin, total hemoglobin, intravascular dyes, and/or water content. The invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.
Number | Name | Date | Kind |
---|---|---|---|
3998550 | Konishi et al. | Dec 1976 | A |
4066068 | Nilsson et al. | Jan 1978 | A |
4364008 | Jacques | Dec 1982 | A |
4380439 | Kreitenberg | Apr 1983 | A |
4711244 | Kuzara | Dec 1987 | A |
4723554 | Oman et al. | Feb 1988 | A |
4759369 | Taylor | Jul 1988 | A |
4805623 | Jobsis | Feb 1989 | A |
4824242 | Frick et al. | Apr 1989 | A |
4850365 | Rosenthal | Jul 1989 | A |
4859057 | Taylor et al. | Aug 1989 | A |
4860753 | Amerena | Aug 1989 | A |
4863265 | Flower et al. | Sep 1989 | A |
4867557 | Takatani et al. | Sep 1989 | A |
4883055 | Merrick | Nov 1989 | A |
4907594 | Muz | Mar 1990 | A |
4911167 | Corenman et al. | Mar 1990 | A |
4926867 | Kanda et al. | May 1990 | A |
4955379 | Hall | Sep 1990 | A |
4968137 | Yount | Nov 1990 | A |
5025791 | Niwa | Jun 1991 | A |
5057695 | Hirao et al. | Oct 1991 | A |
5086781 | Bookspan | Feb 1992 | A |
5111817 | Clark et al. | May 1992 | A |
5146091 | Knudson | Sep 1992 | A |
5224478 | Sakai et al. | Jul 1993 | A |
5251632 | Delpy | Oct 1993 | A |
5263244 | Centa et al. | Nov 1993 | A |
5267562 | Ukawa et al. | Dec 1993 | A |
5267563 | Swedlow et al. | Dec 1993 | A |
5277181 | Mendelson et al. | Jan 1994 | A |
5278627 | Aoyagi et al. | Jan 1994 | A |
5279295 | Martens et al. | Jan 1994 | A |
5282467 | Piantadosi et al. | Feb 1994 | A |
5297548 | Pologe | Mar 1994 | A |
5299120 | Kaestle | Mar 1994 | A |
5329922 | Atlee, III | Jul 1994 | A |
5337745 | Benaron | Aug 1994 | A |
5337937 | Blank et al. | Aug 1994 | A |
5348004 | Hollub | Sep 1994 | A |
5348005 | Merrick et al. | Sep 1994 | A |
5349519 | Kaestle | Sep 1994 | A |
5355880 | Thomas et al. | Oct 1994 | A |
5355882 | Ukawa et al. | Oct 1994 | A |
5377674 | Kuestner | Jan 1995 | A |
5390670 | Centa et al. | Feb 1995 | A |
5392777 | Swedlow et al. | Feb 1995 | A |
5396893 | Oberg et al. | Mar 1995 | A |
5402777 | Warring et al. | Apr 1995 | A |
5402778 | Chance | Apr 1995 | A |
5408998 | Mersch | Apr 1995 | A |
5417207 | Young et al. | May 1995 | A |
5458562 | Cooper | Oct 1995 | A |
5485847 | Baker, Jr. | Jan 1996 | A |
5490505 | Diab et al. | Feb 1996 | A |
5499627 | Steuer et al. | Mar 1996 | A |
5503148 | Pologe et al. | Apr 1996 | A |
5517988 | Gerhard | May 1996 | A |
5522388 | Ishikawa et al. | Jun 1996 | A |
5524617 | Mannheimer | Jun 1996 | A |
5575285 | Takanashi et al. | Nov 1996 | A |
5584299 | Sakai et al. | Dec 1996 | A |
5595176 | Yamaura | Jan 1997 | A |
5615689 | Kotler | Apr 1997 | A |
5645059 | Fein et al. | Jul 1997 | A |
5662106 | Swedlow et al. | Sep 1997 | A |
5685299 | Diab et al. | Nov 1997 | A |
5687721 | Kuhls | Nov 1997 | A |
5690104 | Kanemoto et al. | Nov 1997 | A |
5701902 | Vari et al. | Dec 1997 | A |
5715816 | Mainiero et al. | Feb 1998 | A |
5720284 | Aoyagi et al. | Feb 1998 | A |
5735284 | Tsoglin et al. | Apr 1998 | A |
5743261 | Mainiero et al. | Apr 1998 | A |
5743263 | Baker, Jr. | Apr 1998 | A |
5743349 | Steinberg | Apr 1998 | A |
5746206 | Mannheimer | May 1998 | A |
5747789 | Godik | May 1998 | A |
5755672 | Arai et al. | May 1998 | A |
5766127 | Pologe et al. | Jun 1998 | A |
5788643 | Feldman | Aug 1998 | A |
5803908 | Steuer et al. | Sep 1998 | A |
5810723 | Aldrich | Sep 1998 | A |
5817008 | Rafert et al. | Oct 1998 | A |
5827181 | Dias et al. | Oct 1998 | A |
5830137 | Scharf | Nov 1998 | A |
5833602 | Osemwota | Nov 1998 | A |
5853364 | Baker, Jr. et al. | Dec 1998 | A |
5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
5871694 | Beden et al. | Feb 1999 | A |
5891025 | Buschmann et al. | Apr 1999 | A |
5902235 | Lewis et al. | May 1999 | A |
5906582 | Kondo et al. | May 1999 | A |
5934277 | Mortz | Aug 1999 | A |
6018673 | Chin et al. | Jan 2000 | A |
6064898 | Aldrich | May 2000 | A |
6073041 | Hu et al. | Jun 2000 | A |
6125297 | Siconolfi | Sep 2000 | A |
6149591 | Henderson et al. | Nov 2000 | A |
6149597 | Kamiyama | Nov 2000 | A |
6151107 | Schollermann et al. | Nov 2000 | A |
6151518 | Hayashi | Nov 2000 | A |
6178342 | Thompson et al. | Jan 2001 | B1 |
6178343 | Bindszus et al. | Jan 2001 | B1 |
6216021 | Franceschini et al. | Apr 2001 | B1 |
6222189 | Misner et al. | Apr 2001 | B1 |
6230035 | Aoyagi et al. | May 2001 | B1 |
6246894 | Steuer et al. | Jun 2001 | B1 |
6258038 | Haryadi et al. | Jul 2001 | B1 |
6263222 | Diab et al. | Jul 2001 | B1 |
6272363 | Casciani et al. | Aug 2001 | B1 |
6278889 | Robinson | Aug 2001 | B1 |
6280396 | Clark et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6299583 | Eggers et al. | Oct 2001 | B1 |
6330468 | Scharf | Dec 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6336044 | Ghiassi et al. | Jan 2002 | B1 |
6339715 | Bahr et al. | Jan 2002 | B1 |
6370426 | Campbell et al. | Apr 2002 | B1 |
6374129 | Chin et al. | Apr 2002 | B1 |
6381480 | Stoddart et al. | Apr 2002 | B1 |
6385471 | Mortz | May 2002 | B1 |
6393310 | Kuenstner | May 2002 | B1 |
6393311 | Edgar, Jr. et al. | May 2002 | B1 |
6397093 | Aldrich | May 2002 | B1 |
6400971 | Finarov et al. | Jun 2002 | B1 |
6402690 | Rhee et al. | Jun 2002 | B1 |
6406267 | Mondiere | Jun 2002 | B1 |
6411832 | Guthermann | Jun 2002 | B1 |
6415236 | Kobayashi et al. | Jul 2002 | B2 |
6438399 | Kurth | Aug 2002 | B1 |
6442408 | Wenzel et al. | Aug 2002 | B1 |
6449501 | Reuss | Sep 2002 | B1 |
6461165 | Takanashi et al. | Oct 2002 | B1 |
6466807 | Dobson et al. | Oct 2002 | B1 |
6480729 | Stone | Nov 2002 | B2 |
6488677 | Bowman et al. | Dec 2002 | B1 |
6494576 | L'Esperance | Dec 2002 | B1 |
6501974 | Huiku | Dec 2002 | B2 |
6512936 | Monfre et al. | Jan 2003 | B1 |
6519486 | Edgar, Jr. et al. | Feb 2003 | B1 |
6526297 | Merilainen | Feb 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6587704 | Fine et al. | Jul 2003 | B1 |
6591122 | Schmitt | Jul 2003 | B2 |
6592574 | Shimmick et al. | Jul 2003 | B1 |
6600946 | Rice | Jul 2003 | B1 |
6606509 | Schmitt | Aug 2003 | B2 |
6615064 | Aldrich | Sep 2003 | B1 |
6615065 | Barrett et al. | Sep 2003 | B1 |
6622095 | Kobayashi et al. | Sep 2003 | B2 |
6635491 | Khalil et al. | Oct 2003 | B1 |
6636759 | Robinson | Oct 2003 | B2 |
6643543 | Takehara et al. | Nov 2003 | B2 |
6647280 | Bahr et al. | Nov 2003 | B2 |
6650917 | Diab et al. | Nov 2003 | B2 |
6654620 | Wu et al. | Nov 2003 | B2 |
6668181 | Wenzel et al. | Dec 2003 | B2 |
6671526 | Aoyagi et al. | Dec 2003 | B1 |
6675029 | Monfre et al. | Jan 2004 | B2 |
6687519 | Steuer et al. | Feb 2004 | B2 |
6702752 | Dekker | Mar 2004 | B2 |
6714803 | Mortz | Mar 2004 | B1 |
6714804 | Al-Ali et al. | Mar 2004 | B2 |
6754515 | Pologe | Jun 2004 | B1 |
6770028 | Ali et al. | Aug 2004 | B1 |
6777240 | Hazen et al. | Aug 2004 | B2 |
6780158 | Yarita | Aug 2004 | B2 |
6801799 | Mendelson | Oct 2004 | B2 |
6810277 | Edgar, Jr. et al. | Oct 2004 | B2 |
6839585 | Lowery et al. | Jan 2005 | B2 |
6842635 | Parker | Jan 2005 | B1 |
6845256 | Chin et al. | Jan 2005 | B2 |
6849046 | Eyal-Bickels | Feb 2005 | B1 |
6859658 | Krug | Feb 2005 | B1 |
6879850 | Kimball | Apr 2005 | B2 |
6898452 | Al-Ali et al. | May 2005 | B2 |
6947780 | Scharf | Sep 2005 | B2 |
6947781 | Asada | Sep 2005 | B2 |
6950699 | Manwaring et al. | Sep 2005 | B1 |
6970792 | Diab | Nov 2005 | B1 |
6987994 | Mort | Jan 2006 | B1 |
7039538 | Baker, Jr. | May 2006 | B2 |
7194293 | Baker, Jr. | Mar 2007 | B2 |
7209774 | Baker, Jr. | Apr 2007 | B2 |
7236811 | Schmitt | Jun 2007 | B2 |
7239902 | Schmitt et al. | Jul 2007 | B2 |
7263395 | Chan et al. | Aug 2007 | B2 |
7277741 | Debreczeny et al. | Oct 2007 | B2 |
20010020122 | Steuer et al. | Sep 2001 | A1 |
20030060693 | Monfre et al. | Mar 2003 | A1 |
20040127777 | Ruchti et al. | Jul 2004 | A1 |
20040147034 | Gore et al. | Jul 2004 | A1 |
20040230106 | Schmitt et al. | Nov 2004 | A1 |
20040249252 | Fine et al. | Dec 2004 | A1 |
20050197552 | Baker, Jr. | Sep 2005 | A1 |
20050197579 | Baker, Jr. | Sep 2005 | A1 |
20050256386 | Chan et al. | Nov 2005 | A1 |
20060020181 | Schmitt | Jan 2006 | A1 |
20060084864 | Schmitt et al. | Apr 2006 | A1 |
20060167350 | Monfre et al. | Jul 2006 | A1 |
20060200015 | Baker, Jr. | Sep 2006 | A1 |
20060224053 | Black et al. | Oct 2006 | A1 |
20060253007 | Cheng et al. | Nov 2006 | A1 |
20060253016 | Baker, Jr. et al. | Nov 2006 | A1 |
20060276696 | Schurman | Dec 2006 | A1 |
20070032714 | Mannheimer | Feb 2007 | A1 |
20070077200 | Baker, Jr. | Apr 2007 | A1 |
20070100220 | Baker, Jr. | May 2007 | A1 |
20070106137 | Baker et al. | May 2007 | A1 |
20070118027 | Baker, Jr. et al. | May 2007 | A1 |
20070129614 | Schmitt et al. | Jun 2007 | A1 |
20070208242 | Baker, Jr. | Sep 2007 | A1 |
20080077022 | Baker | Mar 2008 | A1 |
20080221417 | Baker et al. | Sep 2008 | A1 |
20080221462 | Baker | Sep 2008 | A1 |
Number | Date | Country |
---|---|---|
2353007 | Jun 2000 | CA |
19855521 | Jun 2000 | DE |
1135184 | Jun 2000 | EP |
1184663 | Mar 2002 | EP |
2710517 | Apr 1995 | FR |
4-40940 | Feb 1992 | JP |
5-329163 | Dec 1993 | JP |
11-244266 | Sep 1999 | JP |
2004 081427 | Mar 2004 | JP |
WO 9313706 | Jul 1993 | WO |
WO 9519562 | Jul 1995 | WO |
WO 9834097 | Aug 1998 | WO |
WO 0032262 | Jun 2000 | WO |
WO 0071025 | Nov 2000 | WO |
WO 0116577 | Mar 2001 | WO |
WO 03010510 | Feb 2003 | WO |
WO 2005041765 | May 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20080221463 A1 | Sep 2008 | US |